NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYOND.

Francesco Cappello, Valentina Guarnotta, Giovanni Tomasello, Dario Raimondo, Emanuele Sinagra, Georgios Amvrosiadis, Gaetano Cristian Morreale, Francesca Rossi, Ghazaleh Mohammadian, Giorgio Fusco, Giovanni Tomasello, Francesco Cappello, Francesco Cappello

Risultato della ricerca: Article

11 Citazioni (Scopus)

Abstract

Irritable bowel syndrome (IBS) is a chronic, recurring,and remitting functional disorder of the gastrointestinaltract characterized by abdominal pain, distention, andchanges in bowel habits. Although there are severaldrugs for IBS, effective and approved treatments forone or more of the symptoms for various IBS subtypesare needed. Improved understanding of pathophysiologicalmechanisms such as the role of impaired bileacid metabolism, neurohormonal regulation, immune, dysfunction, the epithelial barrier and the secretoryproperties of the gut has led to advancements in thetreatment of IBS. With regards to therapies for restoringintestinal permeability, multiple studies with prebioticsand probiotics are ongoing, even if to date their efficacyhas been limited. In parallel, much progress has beenmade in targeting low-grade inflammation, especiallythrough the introduction of drugs such as mesalazineand rifaximin, even if a better knowledge of themechanisms underlying the low-grade inflammation inIBS may allow the design of clinical trials that test theefficacy and safety of such drugs. This literature reviewaims to summarize the findings related to new andinvestigational therapeutic agents for IBS, most recentlydeveloped in preclinical as well as Phase 1 and Phase 2clinical studies.
Lingua originaleEnglish
pagine (da-a)6593-6627
Numero di pagine35
RivistaDefault journal
Volume36
Stato di pubblicazionePublished - 2017

Fingerprint

Irritable Bowel Syndrome
Inflammation
rifaximin
Therapeutics
Probiotics
Pharmaceutical Preparations
Abdominal Pain
Habits
Permeability
Clinical Trials
Safety

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cita questo

NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYOND. / Cappello, Francesco; Guarnotta, Valentina; Tomasello, Giovanni; Raimondo, Dario; Sinagra, Emanuele; Amvrosiadis, Georgios; Morreale, Gaetano Cristian; Rossi, Francesca; Mohammadian, Ghazaleh; Fusco, Giorgio; Tomasello, Giovanni; Cappello, Francesco; Cappello, Francesco.

In: Default journal, Vol. 36, 2017, pag. 6593-6627.

Risultato della ricerca: Article

Cappello, F, Guarnotta, V, Tomasello, G, Raimondo, D, Sinagra, E, Amvrosiadis, G, Morreale, GC, Rossi, F, Mohammadian, G, Fusco, G, Tomasello, G, Cappello, F & Cappello, F 2017, 'NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYOND.', Default journal, vol. 36, pagg. 6593-6627.
Cappello, Francesco ; Guarnotta, Valentina ; Tomasello, Giovanni ; Raimondo, Dario ; Sinagra, Emanuele ; Amvrosiadis, Georgios ; Morreale, Gaetano Cristian ; Rossi, Francesca ; Mohammadian, Ghazaleh ; Fusco, Giorgio ; Tomasello, Giovanni ; Cappello, Francesco ; Cappello, Francesco. / NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYOND. In: Default journal. 2017 ; Vol. 36. pagg. 6593-6627.
@article{059e0f932c3f47f797111737f311ec0f,
title = "NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYOND.",
abstract = "Irritable bowel syndrome (IBS) is a chronic, recurring,and remitting functional disorder of the gastrointestinaltract characterized by abdominal pain, distention, andchanges in bowel habits. Although there are severaldrugs for IBS, effective and approved treatments forone or more of the symptoms for various IBS subtypesare needed. Improved understanding of pathophysiologicalmechanisms such as the role of impaired bileacid metabolism, neurohormonal regulation, immune, dysfunction, the epithelial barrier and the secretoryproperties of the gut has led to advancements in thetreatment of IBS. With regards to therapies for restoringintestinal permeability, multiple studies with prebioticsand probiotics are ongoing, even if to date their efficacyhas been limited. In parallel, much progress has beenmade in targeting low-grade inflammation, especiallythrough the introduction of drugs such as mesalazineand rifaximin, even if a better knowledge of themechanisms underlying the low-grade inflammation inIBS may allow the design of clinical trials that test theefficacy and safety of such drugs. This literature reviewaims to summarize the findings related to new andinvestigational therapeutic agents for IBS, most recentlydeveloped in preclinical as well as Phase 1 and Phase 2clinical studies.",
author = "Francesco Cappello and Valentina Guarnotta and Giovanni Tomasello and Dario Raimondo and Emanuele Sinagra and Georgios Amvrosiadis and Morreale, {Gaetano Cristian} and Francesca Rossi and Ghazaleh Mohammadian and Giorgio Fusco and Giovanni Tomasello and Francesco Cappello and Francesco Cappello",
year = "2017",
language = "English",
volume = "36",
pages = "6593--6627",
journal = "Default journal",

}

TY - JOUR

T1 - NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYOND.

AU - Cappello, Francesco

AU - Guarnotta, Valentina

AU - Tomasello, Giovanni

AU - Raimondo, Dario

AU - Sinagra, Emanuele

AU - Amvrosiadis, Georgios

AU - Morreale, Gaetano Cristian

AU - Rossi, Francesca

AU - Mohammadian, Ghazaleh

AU - Fusco, Giorgio

AU - Tomasello, Giovanni

AU - Cappello, Francesco

AU - Cappello, Francesco

PY - 2017

Y1 - 2017

N2 - Irritable bowel syndrome (IBS) is a chronic, recurring,and remitting functional disorder of the gastrointestinaltract characterized by abdominal pain, distention, andchanges in bowel habits. Although there are severaldrugs for IBS, effective and approved treatments forone or more of the symptoms for various IBS subtypesare needed. Improved understanding of pathophysiologicalmechanisms such as the role of impaired bileacid metabolism, neurohormonal regulation, immune, dysfunction, the epithelial barrier and the secretoryproperties of the gut has led to advancements in thetreatment of IBS. With regards to therapies for restoringintestinal permeability, multiple studies with prebioticsand probiotics are ongoing, even if to date their efficacyhas been limited. In parallel, much progress has beenmade in targeting low-grade inflammation, especiallythrough the introduction of drugs such as mesalazineand rifaximin, even if a better knowledge of themechanisms underlying the low-grade inflammation inIBS may allow the design of clinical trials that test theefficacy and safety of such drugs. This literature reviewaims to summarize the findings related to new andinvestigational therapeutic agents for IBS, most recentlydeveloped in preclinical as well as Phase 1 and Phase 2clinical studies.

AB - Irritable bowel syndrome (IBS) is a chronic, recurring,and remitting functional disorder of the gastrointestinaltract characterized by abdominal pain, distention, andchanges in bowel habits. Although there are severaldrugs for IBS, effective and approved treatments forone or more of the symptoms for various IBS subtypesare needed. Improved understanding of pathophysiologicalmechanisms such as the role of impaired bileacid metabolism, neurohormonal regulation, immune, dysfunction, the epithelial barrier and the secretoryproperties of the gut has led to advancements in thetreatment of IBS. With regards to therapies for restoringintestinal permeability, multiple studies with prebioticsand probiotics are ongoing, even if to date their efficacyhas been limited. In parallel, much progress has beenmade in targeting low-grade inflammation, especiallythrough the introduction of drugs such as mesalazineand rifaximin, even if a better knowledge of themechanisms underlying the low-grade inflammation inIBS may allow the design of clinical trials that test theefficacy and safety of such drugs. This literature reviewaims to summarize the findings related to new andinvestigational therapeutic agents for IBS, most recentlydeveloped in preclinical as well as Phase 1 and Phase 2clinical studies.

UR - http://hdl.handle.net/10447/243698

M3 - Article

VL - 36

SP - 6593

EP - 6627

JO - Default journal

JF - Default journal

ER -